Optum Rx Unveils Transparent Pharmacy Care Model
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy UNH?
Source: Newsfilter
- New Pharmacy Care Model: Optum Rx has launched a fundamentally new pharmacy care model that replaces traditional drug pricing with a transparent fee-based structure, expected to enhance client satisfaction by providing clearer and more predictable pharmacy services.
- Fee Transparency: Under the new model, Optum Rx clients will be charged a clearly defined monthly fee per member, eliminating uncertainties associated with fluctuating drug prices, with a full transition to this fixed service fee model anticipated by the end of 2027.
- Digital Tools Empowerment: The introduction of digital tools like Shop MyScript and Price Wise enables patients to gain real-time insights into drug pricing and options immediately after a prescription is written, which is expected to reduce prescription abandonment rates and improve medication decision-making.
- Drug Discount Pass-Through: Optum Rx has committed to passing through 100% of manufacturer drug rebates to clients by 2028, which is expected to significantly lower pharmacy costs for clients and further modernize and enhance the affordability of pharmacy care.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UNH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UNH
Wall Street analysts forecast UNH stock price to fall
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 399.090
Low
330.00
Averages
397.82
High
444.00
Current: 399.090
Low
330.00
Averages
397.82
High
444.00
About UNH
UnitedHealth Group Incorporated is a healthcare and well-being company. Its segments include Optum Health, Optum Insight, Optum Rx, and UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State. Optum Health provides comprehensive and patient-centered care, addressing the physical, mental, and social well-being. Optum Health delivers primary, specialty and surgical care and helps patients and providers navigate and address complex, chronic and behavioral health needs. Optum Insight connects the healthcare system with services, analytics and platforms that make clinical, administrative and financial processes simpler and more efficient for all participants in the healthcare system. Optum Rx offers a range of pharmacy care services through retail pharmacies, through home delivery, specialty and community health pharmacies and the provision of in-home and community-based infusion services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
UnitedHealth Stock Pulls Back, Yet Holds Long-Term Potential
- Stock Pullback: UnitedHealth (UNH) snapped a six-session winning streak, closing down 0.59% at $398.8, despite a 9.6% gain over the past seven sessions, indicating short-term volatility in its stock performance.
- Earnings Beat: The company reported first-quarter revenue of $111.7 billion, up 2% year-over-year and above estimates, while adjusted earnings per share of $7.23 exceeded expectations by $0.63, reflecting strong profitability.
- Optimistic Outlook: UnitedHealth raised its full-year 2026 adjusted EPS outlook to over $18.25 from prior guidance of above $17.75, demonstrating confidence in future growth, particularly through premium repricing and AI-driven cost savings.
- Market Analysis: Despite concerns over elevated medical loss ratios and reimbursement uncertainties, 22 Wall Street analysts rated the stock as a Buy, indicating strong market confidence, especially after the company exited unprofitable Medicare Advantage markets, losing about 1 million members.
See More
UnitedHealth Stock Soars 47%, Leading Dow Jones Recovery
- Stock Surge: Since February 10, UnitedHealth (UNH) shares have surged 47%, making it the best-performing component of the Dow Jones, outpacing AI winners like Amazon and Nvidia, indicating a robust market rebound.
- Optimistic Financial Outlook: The CFO at Bank of America’s Healthcare Conference stated that strong first-quarter results suggest a turnaround by 2028, with Optum Health posting $1.3 billion in adjusted operating profit, exceeding analyst expectations and signaling recovery.
- Political Tailwind: Trump's multiple UNH stock purchases in Q1, including a trade valued between $100,001 and $250,000 on January 23, have provided additional political momentum, reflecting increased market confidence in the company.
- AI Investment Strategy: UnitedHealth plans to invest $1.5 billion in AI this year, expecting at least a two-to-one return on investment, with AI applications aimed at streamlining healthcare administration and reducing prior authorization requirements by 30% by the end of 2027, further driving business growth.
See More
Dow Jones Industrial Average Rebounds
- Dow Rebound: The Dow Jones Industrial Average regained the 50,000 level on Thursday, closing at 50,063.46 after a gain of over 370 points, driven significantly by strong performances from AI-related technology stocks.
- AI Stock Performance: Since February 6, five AI stocks including Cisco, Nvidia, Amazon, Caterpillar, and Apple have been key drivers of the index, with Cisco surging over 13% on Thursday alone, reaching a record high of $119.36.
- Amazon Investment: Amazon allocated $200 billion in capital expenditures for 2026 to enhance its AI offerings, contributing to a 27% increase in its stock price since February, indicating the company's strong commitment to the AI sector.
- UnitedHealth Group: UnitedHealth Group has gained over 45% since February, and following BofA analyst's price target increase to $420, the stock shows further upside potential, reflecting optimistic market sentiment regarding its future performance.
See More
Biosimilar Adoption Hindered by Legal Challenges
- Legal Challenges: Optum Rx CEO John Mahrt highlighted that lawsuits from brand manufacturers are hindering the adoption of biosimilars, despite the company's desire to offer more options, with approximately 60% of customers insured by UnitedHealth.
- Transparent Pricing Model: On May 11, Optum Rx announced a transparent fee-based model where clients will pay clearly defined monthly fees per member, independent of manufacturers' list prices or prescription volumes, aiming to eliminate spread pricing and similar practices.
- Cost Reduction Initiatives: Mahrt emphasized that Optum is helping to lower medication costs by passing through 100% of drug rebates to plan sponsors and focusing on point-of-sale rebates to enhance economic benefits for clients.
- Support for Policy Reforms: Mahrt expressed support for reforms pushed by the Trump administration and some members of Congress regarding PBM influence, with relevant reforms included in the Consolidated Appropriations Act of 2026, aimed at ensuring 100% rebate pass-throughs and fixed-fee compensation.
See More
Dow Jones Industrial Average Reaches 50,000 Driven by AI Stocks
- Tech-Driven Rebound: The Dow Jones Industrial Average has climbed back to 50,000 for the first time since February 10, primarily driven by stocks linked to artificial intelligence, highlighting the tech sector's dominant role in the economic recovery.
- Amazon's AI Strategy: Amazon's stock has surged 31% since February, as the company enhances its AI offerings by making Alexa the centerpiece of its shopping strategy, which is expected to drive future sales growth.
- UnitedHealth's Strong Performance: UnitedHealth's stock has skyrocketed 47% during the same period, bolstered by strong earnings and solid guidance from management, making it a key contributor to the Dow's return to 50,000, showcasing the resilience of the healthcare sector.
- Mixed Performance Among Stocks: Despite the Dow's rebound, most component stocks have underperformed, indicating a reliance on AI-driven growth, raising questions about the sustainability of the index's rise without support from other stocks.
See More
Goldman Sachs Bullish on UnitedHealth Group's Prospects
- Goldman Sachs Confidence: Goldman Sachs added UnitedHealth Group to its U.S. conviction list, believing that its performance in the Medicare Advantage market is approaching an inflection point, which is expected to drive profit improvement and reflects strong bullish sentiment towards the stock.
- Medicare Advantage Strength: As of March 2026, UnitedHealth serves over 7.5 million Medicare Advantage members, and despite stock volatility over the past 18 months, Goldman Sachs believes the company is nearing the bottom of its underwriting cycle, with potential for future profit growth.
- Positive Market Response: Goldman Sachs' 12-month price target indicates an upside potential of about 12%, and among 28 analysts, 22 rated the stock as a
See More
UnitedHealth Stock Pulls Back, Yet Holds Long-Term Potential
- Stock Pullback: UnitedHealth (UNH) snapped a six-session winning streak, closing down 0.59% at $398.8, despite a 9.6% gain over the past seven sessions, indicating short-term volatility in its stock performance.
- Earnings Beat: The company reported first-quarter revenue of $111.7 billion, up 2% year-over-year and above estimates, while adjusted earnings per share of $7.23 exceeded expectations by $0.63, reflecting strong profitability.
- Optimistic Outlook: UnitedHealth raised its full-year 2026 adjusted EPS outlook to over $18.25 from prior guidance of above $17.75, demonstrating confidence in future growth, particularly through premium repricing and AI-driven cost savings.
- Market Analysis: Despite concerns over elevated medical loss ratios and reimbursement uncertainties, 22 Wall Street analysts rated the stock as a Buy, indicating strong market confidence, especially after the company exited unprofitable Medicare Advantage markets, losing about 1 million members.
See More
UnitedHealth Stock Soars 47%, Leading Dow Jones Recovery
- Stock Surge: Since February 10, UnitedHealth (UNH) shares have surged 47%, making it the best-performing component of the Dow Jones, outpacing AI winners like Amazon and Nvidia, indicating a robust market rebound.
- Optimistic Financial Outlook: The CFO at Bank of America’s Healthcare Conference stated that strong first-quarter results suggest a turnaround by 2028, with Optum Health posting $1.3 billion in adjusted operating profit, exceeding analyst expectations and signaling recovery.
- Political Tailwind: Trump's multiple UNH stock purchases in Q1, including a trade valued between $100,001 and $250,000 on January 23, have provided additional political momentum, reflecting increased market confidence in the company.
- AI Investment Strategy: UnitedHealth plans to invest $1.5 billion in AI this year, expecting at least a two-to-one return on investment, with AI applications aimed at streamlining healthcare administration and reducing prior authorization requirements by 30% by the end of 2027, further driving business growth.
See More
Dow Jones Industrial Average Rebounds
- Dow Rebound: The Dow Jones Industrial Average regained the 50,000 level on Thursday, closing at 50,063.46 after a gain of over 370 points, driven significantly by strong performances from AI-related technology stocks.
- AI Stock Performance: Since February 6, five AI stocks including Cisco, Nvidia, Amazon, Caterpillar, and Apple have been key drivers of the index, with Cisco surging over 13% on Thursday alone, reaching a record high of $119.36.
- Amazon Investment: Amazon allocated $200 billion in capital expenditures for 2026 to enhance its AI offerings, contributing to a 27% increase in its stock price since February, indicating the company's strong commitment to the AI sector.
- UnitedHealth Group: UnitedHealth Group has gained over 45% since February, and following BofA analyst's price target increase to $420, the stock shows further upside potential, reflecting optimistic market sentiment regarding its future performance.
See More
Biosimilar Adoption Hindered by Legal Challenges
- Legal Challenges: Optum Rx CEO John Mahrt highlighted that lawsuits from brand manufacturers are hindering the adoption of biosimilars, despite the company's desire to offer more options, with approximately 60% of customers insured by UnitedHealth.
- Transparent Pricing Model: On May 11, Optum Rx announced a transparent fee-based model where clients will pay clearly defined monthly fees per member, independent of manufacturers' list prices or prescription volumes, aiming to eliminate spread pricing and similar practices.
- Cost Reduction Initiatives: Mahrt emphasized that Optum is helping to lower medication costs by passing through 100% of drug rebates to plan sponsors and focusing on point-of-sale rebates to enhance economic benefits for clients.
- Support for Policy Reforms: Mahrt expressed support for reforms pushed by the Trump administration and some members of Congress regarding PBM influence, with relevant reforms included in the Consolidated Appropriations Act of 2026, aimed at ensuring 100% rebate pass-throughs and fixed-fee compensation.
See More
Dow Jones Industrial Average Reaches 50,000 Driven by AI Stocks
- Tech-Driven Rebound: The Dow Jones Industrial Average has climbed back to 50,000 for the first time since February 10, primarily driven by stocks linked to artificial intelligence, highlighting the tech sector's dominant role in the economic recovery.
- Amazon's AI Strategy: Amazon's stock has surged 31% since February, as the company enhances its AI offerings by making Alexa the centerpiece of its shopping strategy, which is expected to drive future sales growth.
- UnitedHealth's Strong Performance: UnitedHealth's stock has skyrocketed 47% during the same period, bolstered by strong earnings and solid guidance from management, making it a key contributor to the Dow's return to 50,000, showcasing the resilience of the healthcare sector.
- Mixed Performance Among Stocks: Despite the Dow's rebound, most component stocks have underperformed, indicating a reliance on AI-driven growth, raising questions about the sustainability of the index's rise without support from other stocks.
See More
Goldman Sachs Bullish on UnitedHealth Group's Prospects
- Goldman Sachs Confidence: Goldman Sachs added UnitedHealth Group to its U.S. conviction list, believing that its performance in the Medicare Advantage market is approaching an inflection point, which is expected to drive profit improvement and reflects strong bullish sentiment towards the stock.
- Medicare Advantage Strength: As of March 2026, UnitedHealth serves over 7.5 million Medicare Advantage members, and despite stock volatility over the past 18 months, Goldman Sachs believes the company is nearing the bottom of its underwriting cycle, with potential for future profit growth.
- Positive Market Response: Goldman Sachs' 12-month price target indicates an upside potential of about 12%, and among 28 analysts, 22 rated the stock as a
See More
